이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Designing a Large Language Model Architecture for Shared Decision Making and Informed Intentions (DEONCAI3-1)

2026년 9월 15일 업데이트: Felix G. Rebitschek, Harding Center for Risk Literacy

DEONCAi 3-1: Can Large Language Models Support Shared Decision-Making and Informed Intentions in the Field: An Online Experiment Comparing Them to a Standard Model and to an Evidence-Based Decision Aid

This study investigates a novel, agentic Large Language Model (LLM) architecture designed to facilitate Shared Decision-Making (SDM) in healthcare. While patients increasingly use standard LLMs for health information, these models often struggle with multi-turn conversations and fail to adapt to varying reading levels, disadvantaging vulnerable groups. By utilizing an agentic state-machine, this project aims to overcome common LLM deficits-such as context loss and uncritical agreement-to ensure clinically accurate, participatory patient conversations. The study evaluates whether this architecture improves informed decision-making compared to standard LLMs, particularly for patients with low health literacy.

연구 개요

상세 설명

Background & Current State of Research Shared Decision-Making is widely recognized as the gold standard of patient-centered care. However, its successful implementation in clinical practice is frequently hindered by systemic time and budget constraints. Consequently, patients are increasingly turning to Large Language Models to independently access health information and navigate their medical options.

The Problem: Limitations of Standard LLMs Recent studies indicate that using standard LLMs can digitally reproduce existing health inequalities and participation gaps. These models struggle to adapt to different reading levels without a significant loss in quality. While highly developed prompting techniques can enhance clinical accuracy, the results remain highly variable depending on the specific model and technique used.

A central deficit becomes apparent in multi-turn interactions, which are essential for a natural SDM workflow. In these prolonged conversations, standard LLMs tend to exhibit "context rot," leading to a sharp decline in accuracy as the dialogue progresses. This issue is further exacerbated by model sycophancy (an uncritical tendency to agree with the user) and completion eagerness (a tendency to prematurely conclude the conversation). Because current LLMs often fail to meet evidence-based reporting standards and lack systematic validation of user comprehension, the burden of fact-checking remains entirely on the user. This dynamic significantly disadvantages vulnerable groups, particularly those with lower health literacy.

Project Objectives and Research Questions

This project proposes a technical and clinical solution to these challenges through the following core research questions:

Technical-Conceptual Framework: How can we develop a transparent and replicable workflow that formalizes the SDM process through an agentic state-machine, thereby eliminating structural deficits of LLMs (e.g., context rot and sycophancy) in prolonged interactions?

Clinical Evaluation (Primary Objective): Does this newly developed agentic LLM architecture achieve higher scores in participatory conversation management and demonstrate a significantly greater objective increase in informed decision-making among users during multi-turn interactions, compared to a standard baseline LLM?

Health Equity (Secondary Objective): To what extent can this agentic LLM architecture guarantee effective participatory conversation management for vulnerable patient groups with low health literacy?

연구 유형

중재적

등록 (추정된)

330

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

예

설명

Inclusion Criteria:

  • Biological sex: Female.
  • Age: 40 to 70 years old.
  • Country of residence: United States (US) or United Kingdom (UK).
  • Language: Native English speaker (English as first language).
  • Registered and verified user on the academic research platform Prolific.
  • Able to read, understand, and provide informed consent digitally.

Exclusion Criteria:

  • Individuals who do not meet the automated pre-screening criteria on the Prolific platform.
  • Inability to use or access a computer, smartphone, or internet browser required to complete the digital study.

Note: Quotas will be enforced during recruitment to ensure a 50/50 stratified split between participants with and without university entrance qualifications to guarantee variance in educational backgrounds. Once a quota is filled, further participants matching that educational profile will be excluded.

-

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 건강 서비스 연구
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Shared Decision Making Chatbot
Participants will engage in a multi-turn, AI-assisted consultation about mammography screening. They will interact with a newly developed agentic Large Language Model architecture that uses an integrated state-machine designed to actively guide the Shared Decision-Making process, adapt to the user's reading level, and prevent context loss.
An interactive AI chatbot built with an agentic state-machine architecture designed to systematically guide users through the Shared Decision-Making process regarding mammography screening, with built-in ethical guardrails to prevent hallucination and sycophancy.
활성 비교기: Standard Chatbot
Participants will engage in a conversation about mammography screening using a standard, usual care Large Language Model (Mistral Large). This model represents the current consumer standard for AI health queries and lacks the specialized agentic state-machine and SDM workflow guidance.
An unmodified, standard generative Large Language Model chatbot acting as a baseline control, used by participants to discuss mammography screening.
활성 비교기: Information brochure
Participants will receive and read the standard informational patient brochure on mammography screening published by the German Institute for Quality and Efficiency in Health Care (IQWiG). This represents the current standard of care for patient information.
The standard digital informational brochure on mammography screening provided by the german Institute for Quality and Efficiency in Health Care (IQWiG), used as a usual care baseline for patient education.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Patient-Reported Quality of Shared Decision-Making
기간: Day 1
Assessed using the 9-item Shared Decision Making Questionnaire (SDM-Q-9). This validated instrument measures the patient's perceived involvement in the medical decision-making process. The questionnaire consists of 9 items, each rated on a 6-point scale ranging from 0 ("completely disagree") to 5 ("completely agree"). The raw scores are summed and multiplied by 20/9 to yield a total score ranging from 0 to 100. Higher scores indicate a higher perceived quality and greater patient involvement in shared decision-making.
Day 1

2차 결과 측정

결과 측정
측정값 설명
기간
Multidimensional Informed Decision-Making
기간: Day 1
Based on Marteau's conceptualization of informed decision-making. An informed decision is achieved when a participant has sufficient objective knowledge about mammography screening and their behavioral intention (to screen or not to screen) is congruent with their personal attitudes toward the screening. This is calculated as a composite measure integrating an objective knowledge test, an attitude assessment, and a screening intention question. Higher objective knowledge scores and higher attitude-intention congruence indicate a better-informed decision.
Day 1
Subjective Decisional Conflict
기간: Day 1
Assessed using a standardized Decisional Conflict Scale. This measures the participant's perceived uncertainty in choosing a screening option, their clarity of personal values, and their feeling of being supported in decision-making. Scores are transformed to a 0 to 100 scale. Lower scores indicate less decisional conflict and greater decision certainty.
Day 1
Medical Accuracy and Safety of Generated Information
기간: Day 1
A quantitative and qualitative assessment of the medical accuracy of the AI-generated texts. This is operationalized by counting the frequency (number of occurrences) and categorizing the severity of deviations from established medical evidence (i.e., misinformation or "hallucinations"). These deviations are identified via an integrated ethics module and/or expert review. Lower frequencies and lower severity ratings indicate higher medical accuracy.
Day 1

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Felix G Rebitschek, PhD, Harding Center for Risk Literacy

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 9월 15일

기본 완료 (추정된)

2026년 9월 30일

연구 완료 (추정된)

2026년 9월 30일

연구 등록 날짜

최초 제출

2026년 9월 9일

QC 기준을 충족하는 최초 제출

2026년 9월 15일

처음 게시됨 (실제)

2026년 9월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 15일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

De-identified individual participant data (IPD) underlying the results reported in the published article, including survey data (SDM-Q-9, decisional conflict, knowledge scores) and anonymized dialog transcripts, will be shared.

IPD 공유 기간

Data will become available immediately following publication of the primary results and will be accessible indefinitely.

IPD 공유 액세스 기준

Data will be made publicly available as supplement material on the publishers website to any researcher or individual for non-commercial research purposes.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다